CSF3 and infection: In one of these studies, the relative risk of infection-related mortality, early mortality (all-cause mortality during the chemotherapy period), and FN decreased, and that the average RDI significantly increased, in patients receiving G-CSF than in control patients.[5] Another study reported not only a reduction in FN after G-CSF administration, but also the superiority of pegfilgrastim over daily filgrastim, a short-acting G-CSF.